Supported by grants from Carl Zeiss Meditec, Inc. (Dublin, CA, USA), the National Eye Institute (R01EY024158), an unrestricted grant from the Research to Prevent Blindness, Inc., New York, NY, USA, and the National Eye Institute Center Core Grant (P30EY014801) to the Department of Ophthalmology, University of Miami Miller School of Medicine.
Disclosure: F. Zheng, None; Q. Zhang, None; E.H. Motulsky, None; J.R. de Oliveira Dias, None; C.-L. Chen, None; Z. Chu, None; A.R. Miller, None; W. Feuer, None; G. Gregori, Carl Zeiss Meditec (F), P; S. Kubach, Carl Zeiss Meditec (E); M.K. Durbin, Carl Zeiss Meditec (E); R.K. Wang, Carl Zeiss Meditec (F), Tasso, Inc. (F), Insight Photonic Solutions (C), Westface Medical (C), Kowa (C), P; P.J. Rosenfeld, Acucela (C, F), Alcon (C), Apellis (F, I), Boehringer-Ingelheim (C), Carl Zeiss Meditec (C, F), Cell Cure Neurosciences (C), Chengdu Kanghong Biotech (C), Digisight (I), F. Hoffmann-La Roche Ltd. (C), Genentech (C, F), GlaxoSmithKline (F), Astellas Institute for Regenerative Medicine (F), Healios K.K. (C), Hemera Biosciences (C), Isarna Pharmaceuticals (C), MacRegen Inc. (C), Ocudyne (C, I), Ocunexus Therapeutics (C), Tyrogenex (C, F), Unity Biotechnology (C)